Vito Longo

767 total citations
29 papers, 487 citations indexed

About

Vito Longo is a scholar working on Oncology, Epidemiology and Molecular Biology. According to data from OpenAlex, Vito Longo has authored 29 papers receiving a total of 487 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 11 papers in Epidemiology and 8 papers in Molecular Biology. Recurrent topics in Vito Longo's work include Lung Cancer Research Studies (12 papers), Neuroendocrine Tumor Research Advances (9 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Vito Longo is often cited by papers focused on Lung Cancer Research Studies (12 papers), Neuroendocrine Tumor Research Advances (9 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Vito Longo collaborates with scholars based in Italy, Czechia and United Kingdom. Vito Longo's co-authors include Oronzo Brunetti, Domenico Galetta, Antonio Giovanni Solimando, Antonella Licchetta, Antonio Gnoni, Antonella Argentiero, Annamaria Catino, Sabina Delcuratolo, Nicola Silvestris and Pamela Pizzutilo and has published in prestigious journals such as International Journal of Molecular Sciences, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Vito Longo

25 papers receiving 484 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vito Longo Italy 12 284 128 127 95 94 29 487
Xiaowei Dang China 12 224 0.8× 165 1.3× 163 1.3× 82 0.9× 123 1.3× 33 509
Gerry Gin Wai Kwok China 7 343 1.2× 109 0.9× 79 0.6× 131 1.4× 51 0.5× 10 518
Alessio Fabozzi Italy 13 264 0.9× 108 0.8× 221 1.7× 54 0.6× 90 1.0× 32 507
Chiara Spoto Italy 10 279 1.0× 109 0.9× 131 1.0× 155 1.6× 123 1.3× 13 584
Imane El Dika United States 13 214 0.8× 109 0.9× 207 1.6× 75 0.8× 145 1.5× 30 573
Claudia Angela Maria Fulgenzi United Kingdom 12 226 0.8× 85 0.7× 82 0.6× 60 0.6× 63 0.7× 47 416
Petros Fessas United Kingdom 8 341 1.2× 133 1.0× 91 0.7× 141 1.5× 64 0.7× 14 529
Ryan C. Widau United States 10 214 0.8× 86 0.7× 152 1.2× 141 1.5× 81 0.9× 31 468
Chuyu Jing China 13 212 0.7× 79 0.6× 107 0.8× 61 0.6× 138 1.5× 23 432
Mengdie Yuan United States 5 308 1.1× 146 1.1× 76 0.6× 78 0.8× 131 1.4× 10 455

Countries citing papers authored by Vito Longo

Since Specialization
Citations

This map shows the geographic impact of Vito Longo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vito Longo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vito Longo more than expected).

Fields of papers citing papers by Vito Longo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vito Longo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vito Longo. The network helps show where Vito Longo may publish in the future.

Co-authorship network of co-authors of Vito Longo

This figure shows the co-authorship network connecting the top 25 collaborators of Vito Longo. A scholar is included among the top collaborators of Vito Longo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vito Longo. Vito Longo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Longo, Vito, Domenico Galetta, Sara Pilotto, et al.. (2025). Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapy. European Journal of Cancer. 221. 115435–115435. 2 indexed citations
2.
Lenza, María Pia, Vito Longo, F. Albano, et al.. (2025). Molecular Basis of Siglec-7 Recognition by Neisseria meningitidis Serogroup Y CPS: Implications for Immune Evasion. JACS Au. 5(5). 2257–2269. 1 indexed citations
3.
Longo, Vito, Francesco Pesola, Rosanna Lacalamita, et al.. (2024). Successful treatment of a non‐small‐cell lung cancer patient harboring HIP1‐ALK (H28:A20) and CTNNB1 p.S45del with alectinib. Thoracic Cancer. 15(31). 2283–2287. 1 indexed citations
4.
Fasano, Rossella, Simona Serratì, Vito Longo, et al.. (2024). Small-Cell Lung Cancer: Is Liquid Biopsy a New Tool Able to Predict the Efficacy of Immunotherapy?. Biomolecules. 14(4). 396–396. 6 indexed citations
5.
Longo, Vito, Annamaria Catino, Michele Montrone, et al.. (2024). Treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go. International Journal of Molecular Sciences. 25(6). 3237–3237. 10 indexed citations
6.
Montrone, Michele, Gerardo Rosati, Vito Longo, et al.. (2023). Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review. Journal of Clinical Medicine. 12(5). 1833–1833. 8 indexed citations
7.
Longo, Vito, Fabiana Vitiello, Francesca Ambrosio, et al.. (2023). 2001P Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy. Annals of Oncology. 34. S1067–S1067. 1 indexed citations
8.
Longo, Vito, Alessandro Rizzo, Annamaria Catino, Michele Montrone, & Domenico Galetta. (2023). Safety evaluation of immune checkpoint inhibitors combined with chemotherapy for the treatment of small cell lung cancer: A meta‐analysis of randomized controlled trials. Thoracic Cancer. 14(11). 1029–1035. 5 indexed citations
9.
Romano, Francesco Jacopo, Francesca Ambrosio, Vito Longo, et al.. (2022). Neutrophil-to-Lymphocyte Ratio Is a Major Prognostic Factor in Non-small Cell Lung Carcinoma Patients Undergoing First Line Immunotherapy With Pembrolizumab. Cancer Diagnosis & Prognosis. 3(1). 44–52. 16 indexed citations
10.
Longo, Vito, Annamaria Catino, Michele Montrone, Domenico Galetta, & Doménico Ribatti. (2022). Controversial role of mast cells in NSCLC tumor progression and angiogenesis. Thoracic Cancer. 13(21). 2929–2934. 13 indexed citations
11.
Montrone, Michele, Vito Longo, Annamaria Catino, Pamela Pizzutilo, & Domenico Galetta. (2021). Efficacia di pralsetinib in un paziente con adenocarcinoma polmonare in stadio avanzato positivo per riarrangiamento di RET: l’importanza del Comprehensive Genomic Profiling. Recenti Progressi in Medicina. 112(1). 10e–13e. 2 indexed citations
12.
Longo, Vito, Annamaria Catino, Michele Montrone, et al.. (2021). What Are the Biomarkers for Immunotherapy in SCLC?. International Journal of Molecular Sciences. 22(20). 11123–11123. 35 indexed citations
13.
Catino, Annamaria, Domenico Galetta, Lucia Lospalluti, et al.. (2021). P78.12 A Rare Case of Dermatomyositis as Late Immune-Related Toxicity During Anti-PD1 Treatment for Advanced Lung Cancer. Journal of Thoracic Oncology. 16(3). S642–S643.
14.
Longo, Vito, Annamaria Catino, Michele Montrone, et al.. (2020). Esophageal Stricture Caused by ALK-Positive NSCLC Esophageal Metastasis Resolved After a Few Days of Lorlatinib Therapy Without Stent Placement. JTO Clinical and Research Reports. 1(2). 100044–100044. 1 indexed citations
15.
Prelaj, Arsela, Sara Elena Rebuzzi, Pamela Pizzutilo, et al.. (2020). EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non–Small-cell Lung Cancer Treated With Immunotherapy. Clinical Lung Cancer. 21(4). 365–377.e5. 46 indexed citations
16.
Gnoni, Antonio, Oronzo Brunetti, Vito Longo, et al.. (2020). Immune system and bone microenvironment: rationale for targeted cancer therapies. Oncotarget. 11(4). 480–487. 43 indexed citations
17.
Brunetti, Oronzo, Antonio Gnoni, Antonella Licchetta, et al.. (2019). Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib. Medicina. 55(10). 707–707. 54 indexed citations
18.
Gnoni, Antonio, Antonella Licchetta, Riccardo Memeo, et al.. (2019). Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies. Medicina. 55(12). 754–754. 59 indexed citations
19.
Longo, Vito, Oronzo Brunetti, Antonio Gnoni, et al.. (2019). Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Medicina. 55(10). 698–698. 51 indexed citations
20.
Prelaj, Arsela, Sara Elena Rebuzzi, Pamela Pizzutilo, et al.. (2018). Predictive score using clinical and blood biomarkers in advanced non-small cell lung cancer (aNSCLC) patients treated with immunotherapy. Annals of Oncology. 29. x2–x2. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiaowei Dang Breakdown of academic impact, for papers by Gerry Gin Wai Kwok Breakdown of academic impact, for papers by Alessio Fabozzi Breakdown of academic impact, for papers by Chiara Spoto Breakdown of academic impact, for papers by Imane El Dika Breakdown of academic impact, for papers by Claudia Angela Maria Fulgenzi Breakdown of academic impact, for papers by Petros Fessas Breakdown of academic impact, for papers by Ryan C. Widau Breakdown of academic impact, for papers by Chuyu Jing Breakdown of academic impact, for papers by Mengdie Yuan
Rankless by CCL
2026